Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: Measuring the uncertain

Haematologica

Volumn 93, Issue 9, 2008, Pages 1412-1414

  Ziakas, Panayiotis D ^a  

^a HYGEIA HOSPITAL   (Greece)

Author keywords

Essential thrombocythemia; JAK2; Meta analysis; Thrombosis

Indexed keywords

JANUS KINASE 2;

ALLELE; ANGINA PECTORIS; DEEP VEIN THROMBOSIS; FOLLOW UP; GENE MUTATION; HEART INFARCTION; HUMAN; LETTER; LEUKOCYTOSIS; LUNG EMBOLISM; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RISK FACTOR; STROKE; THROMBOCYTHEMIA; TRANSIENT ISCHEMIC ATTACK; WILD TYPE;

HUMANS; JANUS KINASE 2; PHENYLALANINE; RISK FACTORS; THROMBOCYTHEMIA, ESSENTIAL; THROMBOCYTOSIS; THROMBOSIS; UNCERTAINTY; VALINE;

EID: 50849103654     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.12970     Document Type: Letter

References (13)

1. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 V617F mutation in patients with polycythemia vera or essential thrombocythemia. Blood 2007;110:840-6.
2. Antonioli E, Guglielmelli P, Poli G, Bogani C, Pancrazzi A, Longo G, et al. Myeloproliferative Disorders Research Consortium (MPD-RC). Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008;93:41-8.
3. Higgins JPT, hompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J 2003;327:557-60.
4. Heller PG, Lev PR, Salim JP, Kornblihtt LI, Goette NP, Chazarreta CD, et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 2006;77:210-6.
5. Wolanskyj AP, Lasho TL, Schwager SM, McClure RF, Wadleigh M, Lee SJ, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005;131:208-13.
6. Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-3.
7. Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera:the role of neutrophils. Semin Hematol 2005;42:239-47.
8. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, et al. United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.
9. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-6.
10. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 2006;108:2493-4.
11. Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159-66.
12. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E, et al. The GIMEMA CMD-Working Party. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 2008;93:372-80.
13. Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer 2007;109:2279-84.